Assignee
HEPTARES THERAPEUTICS LTD
GB·78 granted patents·23 pending applications·735 citations·filing 2012–2023
Top patents by PatentIndex Score
101 records- 0198US11352342B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Jun 7, 2022·9 cites·10 claims
- 0298US11254656B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Feb 22, 2022·10 cites·10 claims
- 0398US11014880B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted May 25, 2021·9 cites·13 claims
- 0498US10961225B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Mar 30, 2021·11 cites·16 claims
- 0598US9670183B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jun 6, 2017·34 cites·23 claims
- 0697US11834407B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Dec 5, 2023·5 cites·13 claims
- 0797US11773090B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Oct 3, 2023·6 cites·10 claims
- 0897US11319312B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·10 cites·20 claims
- 0997US10973832B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Apr 13, 2021·10 cites·16 claims
- 1097US10689368B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·12 cites·20 claims
- 1197US10329278B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jun 25, 2019·13 cites·17 claims
- 1297US10196380B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Feb 5, 2019·20 cites·16 claims
- 1396US11680053B2Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Jun 20, 2023·2 cites·22 claims
- 1496US11584732B2Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Feb 21, 2023·4 cites·17 claims
- 1596US11091456B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Aug 17, 2021·10 cites·20 claims
- 1696US11034704B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 15, 2021·10 cites·13 claims
- 1796US10981889B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Apr 20, 2021·5 cites·12 claims
- 1896US10759751B2Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Sep 1, 2020·12 cites·18 claims
- 1996US10752610B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·10 cites·20 claims
- 2096US10259787B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 16, 2019·13 cites·8 claims
- 2196US9926297B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·19 cites·18 claims
- 2296US9758506B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Sep 12, 2017·22 cites·20 claims
- 2396US9260505B2Methods for screening for binding partners of G-protein coupled receptorsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Feb 16, 2016·104 cites·20 claims
- 2495US11999745B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2022·Granted Jun 4, 2024·3 cites·31 claims
- 2595US10548884B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Feb 4, 2020·11 cites·17 claims
- 2695US10385039B2Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Aug 20, 2019·13 cites·20 claims
- 2795US9907805B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 6, 2018·15 cites·10 claims
- 2894US12024499B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2022·Granted Jul 2, 2024·2 cites·7 claims
- 2994US10413553B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Sep 17, 2019·11 cites·8 claims
- 3094US10030035B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jul 24, 2018·14 cites·17 claims
- 3194US9669013B2Bicyclic aza compounds as muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jun 6, 2017·14 cites·18 claims
- 3294US9573929B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Feb 21, 2017·12 cites·4 claims
- 3394US9266857B2Bicyclic AZA compounds as muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2013·Granted Feb 23, 2016·23 cites·14 claims
- 3493US10738029B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Aug 11, 2020·12 cites·6 claims
- 3593US10428088B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Oct 1, 2019·11 cites·10 claims
- 3693US10351545B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Jul 16, 2019·10 cites·30 claims
- 3793US10246432B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 2, 2019·9 cites·12 claims
- 3893US10167272B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jan 1, 2019·11 cites·21 claims
- 3993US10112923B21,2,4-triazine-4-amine derivativesHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Oct 30, 2018·20 cites·3 claims
- 4093US9975890B2Bicyclic AZA compounds as muscarinic M1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted May 22, 2018·10 cites·9 claims
- 4193US9187451B2Muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2012·Granted Nov 17, 2015·15 cites·14 claims
- 4292US10858352B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Dec 8, 2020·11 cites·20 claims
- 4392US10787447B2Pharmaceutical compoundsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Sep 29, 2020·11 cites·18 claims
- 4492US10584111B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Mar 10, 2020·7 cites·15 claims
- 4592US10259802B2Bicyclic aza compounds as muscarinic M1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Apr 16, 2019·9 cites·20 claims
- 4691US11324738B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted May 10, 2022·9 cites·18 claims
- 4791US11208396B2Oxime compounds as agonists of the muscarinic M1 and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Dec 28, 2021·9 cites·16 claims
- 4891US10167284B2Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jan 1, 2019·12 cites·20 claims
- 4991US9676745B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Jun 13, 2017·10 cites·9 claims
- 5091US9593106B2Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Mar 14, 2017·20 cites·12 claims
Showing the top 50 of 101 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when HEPTARES THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →